JP2014509313A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509313A5
JP2014509313A5 JP2013552124A JP2013552124A JP2014509313A5 JP 2014509313 A5 JP2014509313 A5 JP 2014509313A5 JP 2013552124 A JP2013552124 A JP 2013552124A JP 2013552124 A JP2013552124 A JP 2013552124A JP 2014509313 A5 JP2014509313 A5 JP 2014509313A5
Authority
JP
Japan
Prior art keywords
nasal
nose
powder
ingested
sucking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013552124A
Other languages
English (en)
Japanese (ja)
Other versions
JP5891249B2 (ja
JP2014509313A (ja
Filing date
Publication date
Priority claimed from DE102011009961A external-priority patent/DE102011009961A1/de
Application filed filed Critical
Publication of JP2014509313A publication Critical patent/JP2014509313A/ja
Publication of JP2014509313A5 publication Critical patent/JP2014509313A5/ja
Application granted granted Critical
Publication of JP5891249B2 publication Critical patent/JP5891249B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013552124A 2011-02-01 2012-01-09 7−アザインドール誘導体 Expired - Fee Related JP5891249B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011009961.1 2011-02-01
DE102011009961A DE102011009961A1 (de) 2011-02-01 2011-02-01 7-Azaindolderivate
PCT/EP2012/000067 WO2012104007A2 (de) 2011-02-01 2012-01-09 7-azaindolderivate

Publications (3)

Publication Number Publication Date
JP2014509313A JP2014509313A (ja) 2014-04-17
JP2014509313A5 true JP2014509313A5 (https=) 2016-01-21
JP5891249B2 JP5891249B2 (ja) 2016-03-22

Family

ID=45554609

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013552124A Expired - Fee Related JP5891249B2 (ja) 2011-02-01 2012-01-09 7−アザインドール誘導体

Country Status (18)

Country Link
US (3) US8981101B2 (https=)
EP (3) EP2746281B1 (https=)
JP (1) JP5891249B2 (https=)
KR (1) KR20140014158A (https=)
CN (3) CN103502247B (https=)
AR (1) AR085110A1 (https=)
AU (1) AU2012213775B2 (https=)
BR (1) BR112013019028A2 (https=)
CA (2) CA3082435A1 (https=)
DE (1) DE102011009961A1 (https=)
EA (1) EA201300873A1 (https=)
ES (3) ES2608317T3 (https=)
HK (1) HK1226394A1 (https=)
IL (1) IL227689A0 (https=)
MX (1) MX2013008212A (https=)
SG (1) SG192133A1 (https=)
WO (1) WO2012104007A2 (https=)
ZA (1) ZA201306542B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
AU2013224420B2 (en) * 2012-02-21 2016-12-15 Merck Patent Gmbh Furopyridine derivatives
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
FR3001219A1 (fr) * 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
SG11201506687RA (en) 2013-03-15 2015-09-29 Plexxikon Inc Heterocyclic compounds and uses thereof
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
NZ729618A (en) 2014-09-26 2018-07-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
WO2016141279A1 (en) * 2015-03-04 2016-09-09 Dana-Farber Cancer Institute, Inc. Salicylate inhibitors of melk and methods of use
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3313834A1 (en) * 2015-06-29 2018-05-02 Merck Patent GmbH Tbk/ikk inhibitor compounds and uses thereof
EP3394044A1 (en) 2015-12-17 2018-10-31 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
US11180495B2 (en) * 2017-06-19 2021-11-23 Abbisko Therapeutics Co., Ltd. Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof
JP7675519B2 (ja) 2017-10-13 2025-05-13 オプナ バイオ ソシエテ アノニム キナーゼを調節するための化合物の固体形態
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
ES3028093T3 (en) 2018-06-07 2025-06-18 Disarm Therapeutics Inc Inhibitors of sarm1
KR20200046680A (ko) * 2018-10-25 2020-05-07 한국과학기술원 Pdk1 저해제를 포함하는 역노화 유도용 조성물
WO2025016273A1 (zh) * 2023-07-14 2025-01-23 拜西欧斯(北京)生物技术有限公司 异喹啉衍生物、包含其的药物组合物以及它们的用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
WO2000071524A1 (en) 1999-05-19 2000-11-30 Smithkline Beecham Plc 2-nh-pyridones and pyrimidones as mrs inhibitors
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
UA87494C2 (en) * 2004-03-30 2009-07-27 Вертекс Фармасьютикалс Инкорпорейтед Azaindoles useful as inhibitors of jak and other protein kinases
TWI372624B (en) * 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
FR2868422B1 (fr) 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2005123672A2 (en) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
EP1828180A4 (en) * 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
JP2008534664A (ja) 2005-04-06 2008-08-28 アストラゼネカ アクチボラグ 置換複素環およびchk1、pdk1及びpak阻害剤としてのそれらの使用
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
JP2007099640A (ja) 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
CN102532133A (zh) 2006-01-17 2012-07-04 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
CA2659582A1 (en) 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
CA2673003A1 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
CA2679694A1 (en) 2007-03-13 2008-09-18 Merck & Co., Inc. Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
ES2395581T3 (es) 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Inhibidores de quinasas janus
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
US8183245B2 (en) 2007-10-25 2012-05-22 Merck Sharp & Dohme Corp. Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1
JP5368485B2 (ja) * 2008-02-25 2013-12-18 エフ.ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼインヒビター
DE102008025751A1 (de) * 2008-05-29 2009-12-03 Merck Patent Gmbh 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102008038221A1 (de) * 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
AU2011258465B2 (en) * 2010-05-24 2016-12-15 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン
DE102010053347A1 (de) 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate

Similar Documents

Publication Publication Date Title
JP2014509313A5 (https=)
JP2013534227A5 (https=)
JP2014526447A5 (https=)
JP2013544781A5 (https=)
JP2013541565A5 (https=)
JP2015505541A5 (https=)
Weber et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art
Doktorovova et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation
EA201590286A1 (ru) Аэрозольное ингаляционное устройство
JP2013538214A5 (https=)
RU2015121091A (ru) Порошки для ингаляции с ультранизкой плотностью
EA201591729A1 (ru) Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства
BR112013022249B8 (pt) Dispositivo de distribuição de droga nasal
WO2014012069A3 (en) Dry powder drug delivery systems and methods
CL2013000153A1 (es) Metodo para entregar una solucion de un medicamento a un ojo de un sujeto que lo necesita, comprende, el proveer gotitas que contienen dicho medicamento, en donde dichas gotitas tienen un tamaño promedio de gotita por lo menos de aproximadamente 15 micrones y una velocidad de eyeccion inicial promedio entre 1 m/s y 5 m/s, y entregar dicho medicamento a dicho ojo, donde entre aproximadamente 80% y 100% de la masa de dichas gotitas es depositado en el ojo.
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
EA201591869A1 (ru) Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой
JP2020527377A5 (https=)
WO2005084638A3 (en) Formulations decreasing infectivity of pulmonary diseases
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
EP4233874A3 (en) Acetylsalicylic acid for reducing the risk of a thromboembolic event
MD20160061A2 (ro) Sistem de livrare a medicamentului compus din particule multiple
EA201590734A8 (ru) Вдыхаемые лекарственные средства
HK1215167A1 (zh) 可吸入药用组合物和含有该药用组合物的吸入器装置
WO2015006095A3 (en) Apparatus for mixing and transferring medications